News Gilead cleared to restart trials of CD47 drug magrolimab Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion
News Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill... Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.
Events Partner Content 2nd Macrophage-directed Therapies Summit Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.